Drug Trial Radar · NCT06390774
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
Last checked: Nov 20, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
May 30, 2024
Primary completion
Dec 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.
Conditions
- Locally Advanced, Recurrent or Metastatic Malignancies
Interventions
SSGJ-705Drug
anti-PD-1 and anti-HER2 bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTsTime frame: 14 days
- AETime frame: up to 1 year
- MTD or MADTime frame: up to 1 year
- RP2DTime frame: up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.